Compound 52 (Figure 18) has been found to have an excellent DYRK1B inhibitory enzymic activity with an IC50 = 3 nM, cell proliferation inhibitory activity (IC50 = 1.6 μM) against HCT116 colon cancer cells, and inhibitory activity in a patient-derived colon cancer organoids model and a 3D spheroids assay model of SW480 and SW620 [18,19]. Here, DYRK1B is linked to colonic neoplasm.